Disease Landscape and Forecast Insights

Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…

Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of…

Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of…

Insomnia is a prevalent sleep disorder characterized by daytime dysfunction as a result of one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…

Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations across the Europe pharmaceutical markets. We report the prevalence of insomnia for each…

Insomnia is a prevalent sleep disorder characterized by daytime dysfunction as a result of one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…

Insomnia is a highly prevalent condition with obvious indirect economic costs, but payers may not be fully aware of the healthcare cost savings that could result from ensuring patient access to…

Insomnia is a prevalent sleep disorder characterized by daytime dysfunction as a result of one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…

Insomnia is a highly prevalent sleep disorder characterized by daytime dysfunction resulting from sleep problems. The treatment of insomnia is highly individualized, and physicians consider…

Clinical insomnia, estimated to affect 30 million people in the United States, is characterized by daytime dysfunction as a consequence of one or more of the following sleep problems: difficulty…

In the Highly Genericized Insomnia Market, What Opportunities Remain for New Therapies? We expect the prevalence of insomnia in the seven major pharmaceutical markets under study (United States…

In the Highly Genericized Insomnia Market, What Opportunities Remain for New Therapies? We expect the prevalence of insomnia in the seven major pharmaceutical markets under study (United States…